Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.
2.

Genomic analysis defines a cancer-specific gene expression signature for human squamous cell carcinoma and distinguishes malignant hyperproliferation from benign hyperplasia.

Haider AS, Peters SB, Kaporis H, Cardinale I, Fei J, Ott J, Blumenberg M, Bowcock AM, Krueger JG, Carucci JA.

J Invest Dermatol. 2006 Apr;126(4):869-81.

4.

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute DJ, Riggs BL, Horvath S, Liau LM, Cavenee WK, Rao PN, Beroukhim R, Peck TC, Lee JC, Sellers WR, Stokoe D, Prados M, Cloughesy TF, Sawyers CL, Mischel PS.

N Engl J Med. 2005 Nov 10;353(19):2012-24. Erratum in: N Engl J Med. 2006 Feb 23;354(8):884.

5.

Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.

Bell DW, Lynch TJ, Haserlat SM, Harris PL, Okimoto RA, Brannigan BW, Sgroi DC, Muir B, Riemenschneider MJ, Iacona RB, Krebs AD, Johnson DH, Giaccone G, Herbst RS, Manegold C, Fukuoka M, Kris MG, Baselga J, Ochs JS, Haber DA.

J Clin Oncol. 2005 Nov 1;23(31):8081-92. Epub 2005 Oct 3.

6.

Stromagenesis: the changing face of fibroblastic microenvironments during tumor progression.

Beacham DA, Cukierman E.

Semin Cancer Biol. 2005 Oct;15(5):329-41. Review.

PMID:
15970443
7.

Structure-function relationships among human cathelicidin peptides: dissociation of antimicrobial properties from host immunostimulatory activities.

Braff MH, Hawkins MA, Di Nardo A, Lopez-Garcia B, Howell MD, Wong C, Lin K, Streib JE, Dorschner R, Leung DY, Gallo RL.

J Immunol. 2005 Apr 1;174(7):4271-8.

8.

Inflammation and cancer: the long reach of Ras.

Karin M.

Nat Med. 2005 Jan;11(1):20-1. No abstract available.

PMID:
15635437
9.

Nonmelanoma skin cancer mortality (1988-2000): the Rhode Island follow-back study.

Lewis KG, Weinstock MA.

Arch Dermatol. 2004 Jul;140(7):837-42.

PMID:
15262694
11.

Epidermal growth factor receptor-mediated activation of Stat3 during multistage skin carcinogenesis.

Chan KS, Carbajal S, Kiguchi K, Clifford J, Sano S, DiGiovanni J.

Cancer Res. 2004 Apr 1;64(7):2382-9.

12.

Signal transduction and oncogenesis by ErbB/HER receptors.

Marmor MD, Skaria KB, Yarden Y.

Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):903-13. Review.

PMID:
14967450
13.

Fundamental concepts of the angiogenic process.

Folkman J.

Curr Mol Med. 2003 Nov;3(7):643-51. Review.

PMID:
14601638
14.

Origin of the human basal cell epithelioma.

ZACKHEIM HS.

J Invest Dermatol. 1963 Jun;40:283-97. No abstract available.

15.
16.

Epidermal growth factor as a biologic switch in hair growth cycle.

Mak KK, Chan SY.

J Biol Chem. 2003 Jul 11;278(28):26120-6. Epub 2003 Apr 24.

17.

Assembly of cell regulatory systems through protein interaction domains.

Pawson T, Nash P.

Science. 2003 Apr 18;300(5618):445-52. Review.

PMID:
12702867
18.

EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization.

Ferguson KM, Berger MB, Mendrola JM, Cho HS, Leahy DJ, Lemmon MA.

Mol Cell. 2003 Feb;11(2):507-17.

19.

The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors.

Garrett TP, McKern NM, Lou M, Elleman TC, Adams TE, Lovrecz GO, Kofler M, Jorissen RN, Nice EC, Burgess AW, Ward CW.

Mol Cell. 2003 Feb;11(2):495-505.

20.

The role of growth factor signaling in malignancy.

Herbst RS, Onn A, Mendelsohn J.

Cancer Treat Res. 2003;115:19-72. Review. No abstract available.

PMID:
12613192
Items per page

Supplemental Content

Write to the Help Desk